Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Trials

36 clinical trials for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies — RECRUITING · PHASE1
• The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab — RECRUITING · PHASE2
• Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia — RECRUITING · PHASE2
• A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) — RECRUITING · PHASE2
• A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) — RECRUITING · PHASE3
• DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) — RECRUITING · PHASE2
• Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader — RECRUITING · PHASE1
• The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients — RECRUITING · NA
• Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors — RECRUITING · NA
• LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This — RECRUITING · PHASE2
• A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) — TERMINATED · PHASE3
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study) — TERMINATED · PHASE3
• A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313) — TERMINATED · PHASE3
• A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) — TERMINATED · PHASE3
• A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-321) — TERMINATED · PHASE3
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or Small Lymphocytic Lymphoma. AETHER study (ABT199 + Epcoritamab THErapy for Relapsed/refractory CLL/SLL) — TERMINATED · PHASE2
• Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — NOT_YET_RECRUITING · PHASE2
• Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment — COMPLETED · PHASE2
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies — COMPLETED · PHASE1
• A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL — COMPLETED · PHASE1
• Fixed-duration therapy with ibrutinib and obinutuzumab (GA-101) in treatment-naïve patients with CLL — TERMINATED · PHASE2
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant — COMPLETED · PHASE2
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) — NOT_YET_RECRUITING
• Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies — COMPLETED
• Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia — COMPLETED
• Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) — WITHDRAWN · PHASE2
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL — OTHER · PHASE2
• PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies — OTHER · PHASE1
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — COMPLETED · PHASE2
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma — COMPLETED · PHASE2

Refine this search